Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment

Antonio Di Sabatino; Francesca Santilli; Marco Guerci; Paola Simeone; Sandro Ardizzone; Alessandro Massari; Paolo Giuffrida; Romina Tripaldi; Alessandro Malara; Rossella Liani; Evelyn Gurini; Nicola Aronico; Alessandra Balduini; Gino Roberto Corazza; Giovanni Davì

doi:10.1160/TH16-02-0167

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2016; 116(03): 486-495
DOI: 10.1160/TH16-02-0167

Cellular Haemostasis and Platelets

Schattauer GmbH

Oxidative stress and thromboxane-dependent platelet activation in inflammatory bowel disease: effects of anti-TNF-α treatment

Antonio Di Sabatino

²First Department of Internal Medicine and Biotechnology Laboratories

,

Francesca Santilli

¹Internal Medicine and Center of Excellence on Aging, “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy

,

Marco Guerci

²First Department of Internal Medicine and Biotechnology Laboratories

,

Paola Simeone

¹Internal Medicine and Center of Excellence on Aging, “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy

,

Sandro Ardizzone

⁴Division of Gastroenterology, “L. Sacco” University Hospital, Milan, Italy

,

Alessandro Massari

⁴Division of Gastroenterology, “L. Sacco” University Hospital, Milan, Italy

,

Paolo Giuffrida

²First Department of Internal Medicine and Biotechnology Laboratories

,

Romina Tripaldi

¹Internal Medicine and Center of Excellence on Aging, “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy

,

Alessandro Malara

³Department of Molecular Medicine, University of Pavia, IRCCS San Matteo Foundation, Pavia, Italy

,

Rossella Liani

¹Internal Medicine and Center of Excellence on Aging, “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy

,

Evelyn Gurini

³Department of Molecular Medicine, University of Pavia, IRCCS San Matteo Foundation, Pavia, Italy

,

Nicola Aronico

²First Department of Internal Medicine and Biotechnology Laboratories

,

Alessandra Balduini

³Department of Molecular Medicine, University of Pavia, IRCCS San Matteo Foundation, Pavia, Italy

,

Gino Roberto Corazza

²First Department of Internal Medicine and Biotechnology Laboratories

,

Giovanni Davì

¹Internal Medicine and Center of Excellence on Aging, “G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy

› Author Affiliations

Abstract

Summary

Patients with inflammatory bowel disease (IBD) are at higher risk of venous thromboembolism and coronary artery disease despite having a lower burden of traditional risk factors. Platelets from IBD patients release more soluble CD40 ligand (CD40L), and this has been implicated in IBD platelet hyper-activation. We here measured the urinary F₂-isoprostane 8-iso-prostaglandin (PG)_2α (8-iso-PGF_2α), urinary 11–dehydro–thromboxane (TX) B₂ (11-dehydro–TXB₂) and plasma CD40L in IBD patients, and explored the in vitro action of anti-tumour necrosis factor (TNF)–α antibody infliximab on IBD differentiating megakaryocytes. Urinary and blood samples were collected from 124 IBD patients and 37 healthy subjects. Thirteen IBD patients were also evaluated before and after 6–week infliximab treatment. The in vitro effect of infliximab on patient-derived megakaryocytes was evaluated by immunoflorescence microscopy and by flow cytometry. IBD patients had significantly (p<0.0001) higher urinary 8–iso–PGF_2α and 11–dehydro–TXB₂ as well as plasma CD40L levels than controls, with active IBD patients displaying higher urinary and plasma values when compared to inactive patients in remission. A 6-week treatment with infliximab was associated with a significant reduction of the urinary excretion of 8–iso–PGF_2α and 11–dehydro–TXB₂ (p=0.008) and plasma CD40L (p=0.001). Infliximab induced significantly rescued pro-platelet formation by megakaryocytes derived from IBD patients but not from healthy controls. Our findings provide evidence for enhanced in vivo TX–dependent platelet activation and lipid peroxidation in IBD patients. Anti-TNF–α therapy with infliximab down-regulates in vivo isoprostane generation and TX biosynthesis in responder IBD patients. Further studies are needed to clarify the implication of infliximab induced-proplatelet formation from IBD megakaryocytes.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

CD40 ligand - Crohn’s disease - infliximab - lipid peroxidation - platelet activation - ulcerative colitis

Full Text

References

References
1 Tan VP, Chung A, Yan BP. et al. Venous and arterial disease in inflammatory bowel disease. J Gastroenterol Hepatol 2013; 28: 1095-1113.
2 Rungoe C, Nyboe Andersen N, Jess T.. Inflammatory bowel disease and risk of coronary heart disease. Trends Cardiovasc Med 2015; 25: 699-704.
3 Yan SL, Russell J, Harris NR. et al. Platelet abnormalities during colonic inflammation. Inflamm Bowel Dis 2013; 19: 1245-1253.
4 Stadnicki A.. Involvement of coagulation and hemostasis in inflammatory bowel diseases. Curr Vasc Pharmacol 2012; 10: 659-669.
5 Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
6 Ferroni P, Vazzana N, Riondino S. et al. Platelet function in health and disease: from molecular mechanisms, redox considerations to novel therapeutic opportunities. Antioxid Redox Signal 2012; 17: 1447-1485.
7 Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-3384.
8 Yoshida H, Granger N.. Inflammatory bowel disease: a paradigm for the link between coagulation and inflammation. Inflamm Bowel Dis 2009; 15: 1245-1255.
9 Schaufelberger HD, Uhr MR, McGuckin C. et al. Platelets in ulcerative colitis and Crohn's disease express functional interleukin-1 and interleukin-8 receptors. Eur J Clin Invest 1994; 24: 656-663.
10 Danese S, de la Motte C, Sturm A. et al. Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology 2003; 124: 1249-1264.
11 Santilli F, D’Ardes D, Davì G.. Oxidative stress in chronic vascular disease: from prediction to prevention. Vascul Pharmacol 2015; 74: 23-37.
12 Best WR, Becktel JM, Singleton JW. et al. Development of a Crohn's disease activity index: National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444.
13 Rachmilewitz D.. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomized study. Br Med J 1989; 298: 82-86.
14 Ciabattoni G, Pugliese F, Davi G. et al. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim Biophys Acta 1989; 992: 66-70.
15 Wang Z, Ciabattoni G, Créminon C. et al. Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. J Pharmacol Exp Ther 1995; 275: 94-100.
16 Currao M, Malara A, Di Buduo CA. et al. Hyaluronan based hydrogels provide an improved model to study megakaryocyte-matrix interactions. Exp Cell Res. 2015 Epub ahead of print.
17 Di Sabatino A, Rovedatti L, Vidali F. et al. Recent advances in understanding Crohn's disease. Intern Emerg Med 2013; 8: 101-103.
18 Di Sabatino A, Biancheri P, Rovedatti L. et al. Recent advances in understanding ulcerative colitis. Intern Emerg Med 2012; 7: 103-111.
19 Moura FA.. Antioxidant therapy for treatment of inflammatory bowel disease: Does it work?. Redox Biol 2015; 6: 617-639.
20 Minderhoud IM, Steyerberg EW, van Bodegraven AA. et al. Predicting endoscopic disease activity in Crohn's disease: a new and validated noninvasive disease activity index (the Utrecht activity index). Inflamm Bowel Dis 2015; 21: 2453-2459.
21 Singh S, Singh H, Loftus Jr EV. et al. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta- analysis. Clin Gastroenterol Hepatol 2014; 12: 382-393.
22 Danese S, de la Motte C, Fiocchi C.. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004; 99: 938-945.
23 Senchenkova E, Seifert H, Granger DN.. Hypercoagulability and platelet abnormalities in inflammatory bowel disease. Semin Thromb Hemost 2015; 41: 582-589.
24 Collins CE, Cahill MR, Newland AC. et al. Platelets circulate in an activated state in inflammatory bowel disease. Gastroenterology 1994; 106: 840-845.
25 Collins CE, Rampton DS, Rogers J. et al. Platelet aggregation and neutrophil sequestration in the mesenteric circulation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997; 9: 1213-1217.
26 Senhaji N, Kojok K, Darif Y. et al. The contribution of CD40/CD40L axis in inflammatory bowel disease: an update. Front Immunol 2015-16 6 529.
27 Ferroni P, Riondino S, Vazzana N. et al. Biomarkers of platelet activation in acute coronary syndromes. Thromb Haemost 2012; 108: 1109-1123.
28 Menchen L, Marín-Jiménez I, Arias-Salgado EG. et al. Matrix metalloproteinase 9 is involved in Crohn's disease-associated platelet hyperactivation through the release of soluble CD40 ligand. Gut 2009; 58: 920-928.
29 Fitzgerald DJ, Roy L, Catella F. et al. Platelet activation in unstable coronary disease. N Engl J Med 1986; 315: 983-989.
30 Kageyama Y, Takahashi M, Ichikawa T. et al. Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol 2008; 26: 73-80.
31 Danese S, Sans M, Scaldaferri F. et al. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J Immunol 2006; 176: 2617-2624.
32 Manfredi AA, Baldini M, Camera M. et al. Anti-TNFαα agents curb platelet activation in patients with rheumatoid arthritis. Ann Rheum Dis. 2016 Epub ahead of print.
33 Ferrante E, Vazzana N, Santilli F. et al. Determinants of thromboxane biosynthesis in rheumatoid arthritis: Role of RAGE and oxidant stress. Free Radic Biol Med 2010; 1 (49) 857-864.
34 Di Sabatino A, Ciccocioppo R, Cinque B. et al. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 2004; 53: 70-77.
35 Bergamaschi G, Di Sabatino A, Albertini R. et al. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica 2010; 95: 199-205.
36 Di Sabatino A, Pender SL, Jackson CL. et al. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 2007; 133: 137-149.
37 Sobolewska A, Wlodarczyk M, Stec-Michalska K. et al. Mean platelet volume in Crohn's disease patients predicts sustained response to a 52-week infliximab therapy: a pilot study. Dig Dis Sci 2016; 61: 542-549.
38 Ramsfiell V, Borge OJ, Cui L. et al. Thrombopoietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34+ CD38-) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and flt 3, and inhibitory effects of TGF-beta and TNF-alpha. J Immunol 1997; 158: 5169-5177.
39 Wong M, Ziring D, Korin Y. et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008; 126: 121-136.
40 Singh S, Kullo IJ, Pardi DS. et al. Epidemiology, risk factors and management of cardiovascular diseases in IBD.. Nat Rev Gastroenterol Hepatol 2015; 12: 26-35.
41 Ungprasert P, Srivali N, Spanuchart I. et al. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2014; 33: 297-304.

Supplementary Material

Online Supplementary Material (PDF)